{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:30:44Z","timestamp":1787056244867,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10637-026-01624-0","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:55:48Z","timestamp":1781078148000},"page":"328-336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG\u00a0330"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6583-5918","authenticated-orcid":false,"given":"Hamid","family":"Bellout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"1624_CR1","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/leu.2012.341","volume":"27","author":"M Aigner","year":"2013","unstructured":"Aigner M, Feulner J, Schaffer S et al (2013) T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33\/CD3-bispecific BiTE antibody construct. Leukemia 27:1107\u20131115","journal-title":"Leukemia"},{"issue":"3","key":"1624_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","volume":"123","author":"C Krupka","year":"2014","unstructured":"Krupka C, Kufer P, Kischel R et al (2014) CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 123(3):356\u2013365","journal-title":"Blood"},{"key":"1624_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","volume":"30","author":"C Krupka","year":"2016","unstructured":"Krupka C, Kufer P, Kischel R et al (2016) Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330. Leukemia 30:484\u2013491","journal-title":"Leukemia"},{"issue":"9","key":"1624_CR4","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","volume":"65","author":"F Ravandi","year":"2024","unstructured":"Ravandi F, Subklewe M, Walter RB et al (2024) Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study. Leuk Lymphoma 65(9):1281\u20131291. https:\/\/doi.org\/10.1080\/10428194.2024.2346755","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"1624_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2019-127977","volume":"134","author":"M Subklewe","year":"2019","unstructured":"Subklewe M et al (2019) Preliminary results from a Phase 1 first-in-human study of AMG 673. Blood 134(Suppl 1):833","journal-title":"Blood"},{"issue":"3","key":"1624_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13742","volume":"17","author":"R Narayan","year":"2024","unstructured":"Narayan R et al (2024) First-in-human study of JNJ-67571244, a CD33$$\\times $$CD3 bispecific antibody. Clin Transl Sci 17(3):e13742","journal-title":"Clin Transl Sci"},{"key":"1624_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40425-018-0432-9","volume":"6","author":"R Jitschin","year":"2018","unstructured":"Jitschin R, Saul D, Braun M et al (2018) CD33\/CD3-bispecific T-cell engaging antibody construct targets myeloid-derived suppressor cells. J Immunother Cancer 6:116","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1624_CR8","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1158\/1535-7163.MCT-13-0956","volume":"13","author":"M Friedrich","year":"2014","unstructured":"Friedrich M, Henn A, Raum T et al (2014) Preclinical characterization of AMG 330, a CD3\/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther 13(6):1549\u20131557","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1624_CR9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009526","volume":"10","author":"KH Harrington","year":"2015","unstructured":"Harrington KH, Gudgeon CJ, Laszlo GS et al (2015) Preclinical evaluation of the anti-CD33 BiTE AMG 330 in primary AML samples. PLoS ONE 10(3):e0120721","journal-title":"PLoS ONE"},{"key":"1624_CR10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1309\/1WMW-CMXX-4WN4-T55U","volume":"118","author":"I Jilani","year":"2002","unstructured":"Jilani I, Estey E, Huh Y et al (2002) Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 118:560\u2013566","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"1624_CR11","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3324\/haematol.2011.043786","volume":"96","author":"MS De Propris","year":"2011","unstructured":"De Propris MS, Raponi S, Diverio D et al (2011) High CD33 expression levels in AML carrying the NPM1 mutation. Haematologica 96(10):1548\u20131551","journal-title":"Haematologica"},{"issue":"4","key":"1624_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","volume":"123","author":"GS Laszlo","year":"2014","unstructured":"Laszlo GS, Gudgeon CJ, Harrington KH et al (2014) Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager antibody, AMG 330, against human AML. Blood 123(4):554\u2013561","journal-title":"Blood"},{"issue":"3","key":"1624_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300174","volume":"19","author":"LG Eissenberg","year":"2024","unstructured":"Eissenberg LG et al (2024) Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564. PLoS ONE 19(3):e0300174","journal-title":"PLoS ONE"},{"key":"1624_CR14","doi-asserted-by":"crossref","unstructured":"Rettig MP et\u00a0al (2018) A CiTE targeting CD33 and PD-1. Blood 132:4060. [ASH abstract.]","DOI":"10.1182\/blood-2018-10-879668"},{"issue":"19","key":"1624_CR15","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood.2024026934","volume":"145","author":"K Linder","year":"2025","unstructured":"Linder K et al (2025) STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia. Blood 145(19):2149\u20132160","journal-title":"Blood"},{"issue":"18","key":"1624_CR16","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Powers G, Luistro L et al (2020) Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv 4(18):4538\u20134549","journal-title":"Blood Adv"},{"issue":"6","key":"1624_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva D, Perova T, Skerget S et al (2024) Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood 144(6):615\u2013628","journal-title":"Blood"},{"issue":"15","key":"1624_CR18","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1182\/bloodadvances.2022009517","volume":"7","author":"M Mhibik","year":"2023","unstructured":"Mhibik M, Gaglione EM, Eik D et al (2023) Cytotoxicity of the CD3$$\\times $$CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting. Blood Adv 7(15):4089\u20134101","journal-title":"Blood Adv"},{"key":"1624_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41408-021-00430-6","volume":"11","author":"HJ van der Horst","year":"2021","unstructured":"van der Horst HJ, de Jonge AV, Hiemstra IH et al (2021) Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J 11:38","journal-title":"Blood Cancer J"},{"issue":"15 suppl","key":"1624_CR20","doi-asserted-by":"publisher","first-page":"7536","DOI":"10.1200\/JCO.2020.38.15_suppl.7536","volume":"38","author":"SK Agarwal","year":"2020","unstructured":"Agarwal SK, Bhagwat S, Mehta K et al (2020) Characterization of clinical pharmacokinetics and exposure-response relationships of AMG 330, a bispecific CD33 T-cell engager antibody construct, in patients with relapsed\/refractory AML. J Clin Oncol 38(15 suppl):7536","journal-title":"J Clin Oncol"},{"key":"1624_CR21","doi-asserted-by":"publisher","unstructured":"Bellout H, Li A, Piatkov K, Bottino D (2026) A generalization of the ternary binding model to membrane-confined systems with finite copy number. https:\/\/doi.org\/10.64898\/2026.04.10.717668.","DOI":"10.64898\/2026.04.10.717668."}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01624-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01624-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01624-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:07:38Z","timestamp":1787054858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01624-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1624"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01624-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This manuscript is based exclusively on analysis and interpretation of previously published, publicly available aggregate data. No new studies involving human participants, identifiable human data, or animals were conducted by the author. Institutional review board approval and informed consent were therefore not required.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}